[1] |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN esTIMates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2018, 68: 394-424.
|
[2] |
Abramovic I, Ulamec M, Katusic Bojanac A, et al. miRNA in prostate cancer: challenges toward translation[J]. Epigenomics, 2020, 12: 543-558.
|
[3] |
Iacona J, Lutz C. miR-146a-5p: expression, regulation, and functions in cancer[J]. Wiley Interdiscip Rev RNA, 2019, 10: e1533. doi: 10.1002/wrna.1533.
|
[4] |
Zhao M, Mishra L, Deng C. The role of TGF-β/SMAD4 signaling in cancer[J]. Int J Biol Sci, 2018, 14: 111-123.
|
[5] |
Zhang Z, Huang Q, Yu L, et al. The role of miRNA in tumor immune escape and miRNA-based therapeutic strategies[J]. Front Immunol, 2021, 12: 807895. doi: 10.3389/fimmu.2021.807895.
|
[6] |
Testa U, Pelosi E, Castelli G, et al. miR-146 and miR-155: two key modulators of immune response and tumor development[J]. Noncoding RNA, 2017, 3:22. doi: 10.3390/ncrna3030022.
|
[7] |
Puhka M, Thierens L, Nicorici D, et al. Exploration of extracellular vesicle miRNAs, targeted mRNAs and pathways in prostate cancer: relation to disease status and progression[J]. Cancers (Basel), 2022, 14: 532. doi: 10.3390/cancers14030532.
|
[8] |
Zhang S, Liu C, Zou X, et al. MicroRNA panel in serum reveals novel diagnostic biomarkers for prostate cancer[J]. PeerJ, 2021, 9: e11441. doi: 10.7717/peerj.11441.
|
[9] |
Fredsøe J, Rasmussen A, Mouritzen P, et al. Profiling of circulating microRNAs in prostate cancer reveals diagno-stic biomarker potential[J]. Diagnostics (Basel), 2020, 10: 188. doi: 10.3390/diagnostics10040188.
|
[10] |
MaruYama T, Chen W, Shibata H. TGF-β and cancer immunotherapy[J]. Biol Pharm Bull, 2022, 45: 155-161.
|
[11] |
Jafari S, Molavi O, Kahroba H, et al. Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer[J]. Cell Mol Life Sci, 2020, 77: 3693-3710.
|